Roland Phillips, MD
Cardiovascular Disease · Saratoga Springs, NYNPI 1508834060
Payments from drug & device makers
Across 737 payments — averaging $449.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$131K
- Takeda Pharmaceuticals U.S.A., Inc.$72K
- Amgen$45K
- Bayer$44K
- Novartis$18K
- AstraZeneca$13K
- plus $9K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 249 | $130,717 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $71,529 |
| Amgen | 28 | $45,299 |
| Bayer | 38 | $43,837 |
| Novartis | 132 | $18,237 |
| AstraZeneca | 14 | $12,881 |
| Boehringer Ingelheim | 38 | $4,986 |
| Pfizer | 44 | $767 |
| Merck | 27 | $466 |
| E.r. Squibb & Sons, L.L.C. | 20 | $336 |
| Novo Nordisk | 15 | $302 |
| Alnylam Pharmaceuticals Inc. | 13 | $297 |
| Johnson & Johnson | 25 | $295 |
| Kiniksa Pharmaceuticals International, PLC | 7 | $204 |
| Sanofi-aventis U.S. LLC | 9 | $194 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $192 |
| Scpharmaceuticals Inc. | 8 | $157 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $131 |
| Astellas Pharma US Inc | 2 | $87 |
| Abiomed | 3 | $81 |
| Sanofi | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 4 | $67 |
| Amarin Pharma, Inc. | 4 | $62 |
| Arbor Pharmaceuticals, Inc. | 2 | $43 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Medtronic | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
| Gilead | 1 | $11 |
| Philips North America LLC | 1 | $11 |
How this compares
$331,447 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Saratoga Springs
- David KandathSaratoga Springs$1.6M
- Nicholas KondoSaratoga Springs$641K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.